Recent News

• 06.13.2025 - Connect Biopharma Presents Data Supporting Rademikibart at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress
• 06.05.2025 - Jefferies Healthcare Conference
• 06.04.2025 - Noble Capital Markets Virtual Conference
• 06.03.2025 - Connect Biopharma Announces Two Oral Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress
• 05.28.2025 - Connect Biopharma to Present at Two Upcoming Investor Conferences in June
• 05.20.2025 - Connect Biopharma Presents Data Supporting Development of Rademikibart at the American Thoracic Society (ATS) 2025 International Conference
• 05.15.2025 - Connect Biopharma Reports First Quarter 2025 Financial Results and Provides Business Update
• 05.14.2025 - Connect Biopharma Initiates Phase 2 Seabreeze STAT COPD Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in COPD
• 05.13.2025 - Connect Biopharma Initiates Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma
• 04.01.2025 - Connect Biopharma Announces Positive Type C Meeting with the FDA for Rademikibart

Recent Filings

• 06.11.2025 - 144 Report of proposed sale of securities
• 06.10.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 06.10.2025 - F-3 Registration statement by foreign private issuers
• 05.15.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.15.2025 - EX-99.1 EX-99.1
• 05.15.2025 - 8-K Current report
• 05.14.2025 - EX-99.1 EX-99.1
• 05.14.2025 - 8-K Current report
• 05.13.2025 - EX-99.1 EX-99.1
• 05.13.2025 - 8-K Current report